Book a demo

Cut patent&paper research from weeks to hours with PatSnap Eureka AI!

Try now
Masimo v. Apple | Patent Lawsuit 22-1631

Masimo, Corp. v. Apple, Inc.

22-1631 Fed. Cir. Closed US10258265B1
Get a prior-art report

Patentability filed 13 Apr 2022 in the United States Court of Appeals for the Federal Circuit and closed 12 Sep 2023, with US10258265B1 asserted. Recorded basis of termination: appeal dismissed in part.

Case recordPatsnap Litigation Data·

Case record

Patent involved
US10258265B1
Application no.
US16/212440
Case no.
22-1631
Verdict cause
Patentability
Court
Fed. Cir.
Court level
Court of Appeals
Case region
District of Columbia
Chief judge
None recorded
Trial level
Appeal
Filed – Closed
13 Apr 2022 – 12 Sep 2023
Duration
517 days
Basis of termination
Appeal Dismissed in Part
Products & marks
Multi-stream data collection system for noninvasive measurement of blood constituents
Validity challenges
2 on record
Source: Patsnap Litigation Data. Case 22-1631, United States Court of Appeals for the Federal Circuit. Open this record in Eureka
Patsnap Eureka

Check this patent against your own product

Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.

Get an FTO claim chart
10,000 free credits to start
Patent at issue
US10258265B1 Active App. US16/212440

Multi-stream data collection system for noninvasive measurement of blood constituents

The present disclosure relates to noninvasive methods, devices, and systems for measuring various blood constituents or analytes, such as glucose. In an embodiment, a light source comprises LEDs and super-luminescent LEDs. The light source emits light at least wavelengths of about 1610 nm, about 1640 nm, and about 1665 nm. In an embodiment, the detector comprises a plurality of photodetectors arranged in a special geometry comprising one of a substantially linear substantially equal spaced geometry, a substantially linear substantially non-equal spaced geometry, and a substantially grid geometry.

Read claims and description in Eureka
Patent standing
Legal status
Active
Granted
16 Apr 2019
Earliest priority
4 Aug 2008
Est. expiry
25 Aug 2028
Validity challenges
2 on recordIPR2020-01520 · Patentability · filed by Masimo Corp.IPR2020-01520 · filed by APPLE INC.
Licences recorded
None recorded
Classification
A61B5/1455A61B5/00A61B5/145
Examiner
WINAKUR, ERIC F
US10258265B1 patent drawing, figure 1
Fig. 1
US10258265B1 patent drawing, figure 2
Fig. 2
Source: Patsnap patent data + case record. Bibliographic fields and drawings reproduced from the published patent document. Break down the claims
Parties & counsel

Parties of record

Counsel of record

Source: case record + Patsnap company data. Attorney names appear as recorded in the docket. Compare both portfolios
Outcome

Basis of termination

From the record · verbatim

“We have considered Masimo’s remaining arguments but find them unpersuasive. For the foregoing reasons, the decision of the Board is affirmed-in-part and reversed-in-part. AFFIRMED-IN-PART AND REVERSED-IN-PART.”

Case 22-1631 · Fed. Cir. · closed 12 September 2023
Source: case record, verbatim. The quoted paragraph is the basis-of-termination text as filed.

Related cases

Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.

FAQ

Frequently asked questions

What is case 22-1631?

22-1631 is a patent patentability brought by Masimo, Corp. against Apple, Inc., filed on 13 Apr 2022 in the United States Court of Appeals for the Federal Circuit. The case closed on 12 September 2023.

Which patent was asserted in 22-1631?

US10258265B1 (“Multi-stream data collection system for noninvasive measurement of blood constituents”), assigned to MASIMO CORPORATION, currently active. The record also lists Multi-stream data collection system for noninvasive measurement of blood constituents.

How was case 22-1631 terminated?

The recorded basis of termination is appeal dismissed in part. The termination text reads: “We have considered Masimo’s remaining arguments but find them unpersuasive. For the foregoing reasons, the decision of the Board is affirmed-in-part and reversed-in-part. AFFIRMED-IN-PART AND REVERSED-IN-PART.”

How long did case 22-1631 take?

517 calendar days, from filing on 13 Apr 2022 to closure on 12 September 2023.

Who were the attorneys and the judge in 22-1631?

Jarom D. Kesler, Jeremiah Helm, Joseph R. Re, Stephen C. Jensen and Stephen W. Larson are recorded as counsel for plaintiff Masimo. Ashley Bolt, Christopher Dryer, Jared Hartzman, Lauren Ann Degnan and Walter Karl Renner appear for defendant Apple.

Answers reproduce fields from the case record for 22-1631 and do not constitute legal advice. Ask your own question

Disclaimer. This page reproduces publicly available court docket data for case 22-1631 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.

Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.

No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.

No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.

Related Litigation Cases

Help us improve this page

Found incorrect or outdated information? Let us know and we'll get it fixed.